Abstract

ABSTRACTAimThis meta-analysis explores the efficacy and adverse event profile of the iStent, an ab interno implant for the treatment of open-angle glaucoma.MethodsA systematic literature search of Ovid MEDLINE and EMBASE was used to identify peer-reviewed original studies that provided efficacy data on the first or second generation iStent for at least five eyes. Intraocular pressure (IOP) was the primary efficacy endpoint, while the number of medication classes was the secondary outcome. Weighted mean differences were reported for continuous endpoints, while a relative risk was computed for dichotomous variables.Review ResultsThe search revealed 545 results, of which 1767 eyes from 28 studies were included. The cohort age was 71.4 ± 5.4 years, and 44.9% of patients were male. There was a significantly greater IOP reduction after the use of two first-generation stents compared to one, irrespective of phacoemulsification status (p < 0.001). Additionally, there was a significantly greater IOP reduction following iStent alone relative to phaco-iStent for the first-generation iStent (p < 0.001) and the iStent inject (p < 0.001). For the first generation stent, combined phaco-iStent provided a greater level of IOP reduction (p < 0.001) and reduction in the number of medication classes relative to phacoemulsification alone (p < 0.001). In total, 22.5% of eyes that received iStent implantation sustained some type of adverse event. The most common adverse events were intraocular pressure elevation, stent blockage or obstruction, stent malposition and hyphema.Conclusion and Clinical SignificanceStatistically significant differences in efficacy outcomes exist between different numbers of stents and the presence or absence of concurrent phacoemulsification.How to cite this article: Popovic M, Campos-Moller X, Saheb H, Ahmed IIK. Efficacy and Adverse Event Profile of the iStent and iStent Inject Trabecular Micro-bypass for Open-angle Glaucoma: A Meta-analysis. J Curr Glaucoma Pract 2018;12(2):67-84.

Highlights

  • Given the irreversible retinal ganglion cell damage resulting from open-angle glaucoma (OAG), current treatment modalities are focused on preserving the structural integrity of the optic nerve and visual function.[1,2,3]

  • There has been increasing interest in the ability of microinvasive glaucoma surgery (MIGS) devices to provide a significant level of Intraocular pressure (IOP) reduction with less severe postoperative adverse events.[8]

  • When examining IOP reduction, there was a significantly greater decrease after two stents compared to one [Weighted mean differences (WMD) = -1.36 mm Hg, 95% confidence intervals (95% CI) = (-1.92 mm Hg, -0.80 mm Hg), p < 0.001]

Read more

Summary

Introduction

In OAG, IOP elevation is often a result of reduced aqueous humor flow through the trabecular meshwork[5] In early stages, ocular hypotensive medications and laser trabeculoplasty have been shown to attenuate glaucoma progression; there are well known issues with compliance, tolerability, persistence, and difficulty of proper instillation.[3,5] In the situations in which these treatments are insufficient in reducing IOP to target pressures according to disease severity, ab externo filtering procedures are utilized to provide a more significant IOP reduction.

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call